SGIOY
Price
$8.61
Change
+$0.04 (+0.47%)
Updated
Jul 25 closing price
Capitalization
12.4B
2 days until earnings call
SUPN
Price
$33.58
Change
+$0.73 (+2.22%)
Updated
Jul 25 closing price
Capitalization
1.84B
10 days until earnings call
Interact to see
Advertisement

SGIOY vs SUPN

Header iconSGIOY vs SUPN Comparison
Open Charts SGIOY vs SUPNBanner chart's image
Shionogi & Co
Price$8.61
Change+$0.04 (+0.47%)
Volume$45.23K
Capitalization12.4B
Supernus Pharmaceuticals
Price$33.58
Change+$0.73 (+2.22%)
Volume$640.36K
Capitalization1.84B
SGIOY vs SUPN Comparison Chart in %
Loading...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SGIOY vs. SUPN commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SGIOY is a Hold and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (SGIOY: $8.61 vs. SUPN: $33.58)
Brand notoriety: SGIOY and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: SGIOY: 62% vs. SUPN: 99%
Market capitalization -- SGIOY: $12.4B vs. SUPN: $1.84B
SGIOY [@Pharmaceuticals: Other] is valued at $12.4B. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SGIOY’s FA Score shows that 2 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • SGIOY’s FA Score: 2 green, 3 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, SGIOY is a better buy in the long-term than SUPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SGIOY’s TA Score shows that 6 TA indicator(s) are bullish while SUPN’s TA Score has 7 bullish TA indicator(s).

  • SGIOY’s TA Score: 6 bullish, 2 bearish.
  • SUPN’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, both SGIOY and SUPN are a good buy in the short-term.

Price Growth

SGIOY (@Pharmaceuticals: Other) experienced а +3.11% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +3.83% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.55%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +75.03%.

Reported Earning Dates

SGIOY is expected to report earnings on Oct 27, 2025.

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.55% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOY($12.4B) has a higher market cap than SUPN($1.84B). SUPN has higher P/E ratio than SGIOY: SUPN (1677.00) vs SGIOY (9.62). SGIOY YTD gains are higher at: 23.709 vs. SUPN (-7.135). SGIOY has higher annual earnings (EBITDA): 242B vs. SUPN (90M). SGIOY has more cash in the bank: 563B vs. SUPN (255M). SUPN has less debt than SGIOY: SUPN (41.5M) vs SGIOY (9.41B). SGIOY has higher revenues than SUPN: SGIOY (427B) vs SUPN (608M).
SGIOYSUPNSGIOY / SUPN
Capitalization12.4B1.84B675%
EBITDA242B90M268,889%
Gain YTD23.709-7.135-332%
P/E Ratio9.621677.001%
Revenue427B608M70,230%
Total Cash563B255M220,784%
Total Debt9.41B41.5M22,677%
FUNDAMENTALS RATINGS
SGIOY vs SUPN: Fundamental Ratings
SGIOY
SUPN
OUTLOOK RATING
1..100
1116
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
280
PRICE GROWTH RATING
1..100
5258
P/E GROWTH RATING
1..100
49100
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOY's Valuation (27) in the null industry is somewhat better than the same rating for SUPN (72) in the Pharmaceuticals Other industry. This means that SGIOY’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (61) in the Pharmaceuticals Other industry is somewhat better than the same rating for SGIOY (100) in the null industry. This means that SUPN’s stock grew somewhat faster than SGIOY’s over the last 12 months.

SGIOY's SMR Rating (2) in the null industry is significantly better than the same rating for SUPN (80) in the Pharmaceuticals Other industry. This means that SGIOY’s stock grew significantly faster than SUPN’s over the last 12 months.

SGIOY's Price Growth Rating (52) in the null industry is in the same range as SUPN (58) in the Pharmaceuticals Other industry. This means that SGIOY’s stock grew similarly to SUPN’s over the last 12 months.

SGIOY's P/E Growth Rating (49) in the null industry is somewhat better than the same rating for SUPN (100) in the Pharmaceuticals Other industry. This means that SGIOY’s stock grew somewhat faster than SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SGIOYSUPN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 19 days ago
59%
Bearish Trend 20 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
61%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AVGE79.890.21
+0.26%
Avantis All Equity Markets ETF
UAPR31.610.07
+0.24%
Innovator U.S. Equity Ultra BffrETF™-Apr
INCE58.690.07
+0.12%
Franklin Income Equity Focus ETF
ISWN20.650.01
+0.03%
Amplify BlackSwan ISWN ETF
PDI19.11-0.01
-0.05%
PIMCO Dynamic Income Fund

SGIOY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGIOY has been loosely correlated with TAK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SGIOY jumps, then TAK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOY
1D Price
Change %
SGIOY100%
+0.41%
TAK - SGIOY
40%
Loosely correlated
-1.23%
ESAIY - SGIOY
36%
Loosely correlated
-0.28%
KMDA - SGIOY
27%
Poorly correlated
-0.77%
SCYX - SGIOY
23%
Poorly correlated
-1.07%
SUPN - SGIOY
22%
Poorly correlated
+2.22%
More

SUPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with DVAX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+2.22%
DVAX - SUPN
37%
Loosely correlated
+1.79%
COLL - SUPN
29%
Poorly correlated
-1.03%
SNDL - SUPN
27%
Poorly correlated
-1.62%
ACET - SUPN
27%
Poorly correlated
-0.54%
AQST - SUPN
27%
Poorly correlated
-1.19%
More